A SARS-CoV-2 cytopathicity dataset generated by high-content screening of a large drug repurposing collection
Open Access
- 26 February 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Scientific Data
- Vol. 8 (1), 1-10
- https://doi.org/10.1038/s41597-021-00848-4
Abstract
SARS-CoV-2 is a novel coronavirus responsible for the COVID-19 pandemic, in which acute respiratory infections are associated with high socio-economic burden. We applied high-content screening to a well-defined collection of 5632 compounds including 3488 that have undergone previous clinical investigations across 600 indications. The compounds were screened by microscopy for their ability to inhibit SARS-CoV-2 cytopathicity in the human epithelial colorectal adenocarcinoma cell line, Caco-2. The primary screen identified 258 hits that inhibited cytopathicity by more than 75%, most of which were not previously known to be active against SARS-CoV-2 in vitro. These compounds were tested in an eight-point dose response screen using the same image-based cytopathicity readout. For the 67 most active molecules, cytotoxicity data were generated to confirm activity against SARS-CoV-2. We verified the ability of known inhibitors camostat, nafamostat, lopinavir, mefloquine, papaverine and cetylpyridinium to reduce the cytopathic effects of SARS-CoV-2, providing confidence in the validity of the assay. The high-content screening data are suitable for reanalysis across numerous drug classes and indications and may yield additional insights into SARS-CoV-2 mechanisms and potential therapeutic strategies.Funding Information
- LOEWE Center for Translational Medicine and Pharmacology (TMP); Fraunhofer cluster of excellence for immune mediated diseases
- LOEWE Center for Translational Medicine and Pharmacology (TMP), Fraunhofer cluster of excellence for immune mediated diseases
- EU Horizon 2020 project EOSC-LIFE
- Johanna Quandt Universitäts-Stiftung
This publication has 53 references indexed in Scilit:
- Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor ActivityMolecular Cancer Therapeutics, 2014
- Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirusJournal of Infection, 2013
- Commentary: Middle East Respiratory Syndrome Coronavirus (MERS-CoV): Announcement of the Coronavirus Study GroupJournal of Virology, 2013
- Simultaneous Treatment of Human Bronchial Epithelial Cells with Serine and Cysteine Protease Inhibitors Prevents Severe Acute Respiratory Syndrome Coronavirus EntryJournal of Virology, 2012
- Drug repurposing from an academic perspectiveDrug Discovery Today: Therapeutic Strategies, 2012
- CoronaviridaePublished by Elsevier BV ,2011
- The SARS-Coronavirus-Host Interactome: Identification of Cyclophilins as Target for Pan-Coronavirus InhibitorsPLoS Pathogens, 2011
- Analysis of ACE2 in polarized epithelial cells: surface expression and function as receptor for severe acute respiratory syndrome-associated coronavirusJournal of General Virology, 2006
- Severe Acute Respiratory Syndrome (SARS)Annals of the New York Academy of Sciences, 2006
- A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening AssaysSLAS Discovery, 1999